[{"id":"64e9f0b1-de60-4d05-9cce-7c1727ea4a59","acronym":"","url":"https://clinicaltrials.gov/study/NCT01950273","created_at":"2021-01-18T08:50:34.112Z","updated_at":"2024-07-02T16:37:07.229Z","phase":"Phase 1","brief_title":"Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma","source_id_and_acronym":"NCT01950273","lead_sponsor":"Boehringer Ingelheim","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • BI 695500 (rituximab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 09/27/2013","start_date":" 09/27/2013","primary_txt":" Primary completion: 12/22/2015","primary_completion_date":" 12/22/2015","study_txt":" Completion: 12/22/2015","study_completion_date":" 12/22/2015","last_update_posted":"2018-09-05"}]